Fax: (410) 502-0621
Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia†
A Gynecologic Oncology Group study
Version of Record online: 6 JAN 2006
Copyright © 2006 American Cancer Society
Volume 106, Issue 4, pages 812–819, 15 February 2006
How to Cite
Trimble, C. L., Kauderer, J., Zaino, R., Silverberg, S., Lim, P. C., Burke, J. J., Alberts, D. and Curtin, J. (2006), Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia. Cancer, 106: 812–819. doi: 10.1002/cncr.21650
See referenced commentary and companion article on pages 729–31 and 804–11, this issue.
- Issue online: 3 FEB 2006
- Version of Record online: 6 JAN 2006
- Manuscript Accepted: 25 AUG 2005
- Manuscript Revised: 24 AUG 2005
- Manuscript Received: 26 MAY 2005
- National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office. Grant Number: CA 27469
- Gynecologic Oncology Group Statistical and Data Center. Grant Number: CA 37517
- consensus diagnosis;
- endometrial hyperplasia;
- endometrioid adenocarcinoma;
Adenocarcinoma of the endometrium is the most common gynecologic malignancy in the United States, accounting for approximately 36,000 diagnoses of invasive carcinoma annually. The most common histologic type, endometrioid adenocarcinoma (EC), accounts for 75–80% of patients. The objective of this work was to estimate the prevalence of concurrent carcinoma in women with a biopsy diagnosis of the precursor lesion, atypical endometrial hyperplasia (AEH).
This prospective cohort study included women who had a community diagnosis of AEH. Diagnostic biopsy specimens were reviewed independently by three gynecologic pathologists who used International Society of Gynecologic Pathologists/World Health Organization criteria. Study participants underwent hysterectomy within 12 weeks of entry onto protocol without interval treatment. The hysterectomy slides also were reviewed by the study pathologists, and their findings were used in the subsequent analyses.
Between November 1998 and June 2003, 306 women were enrolled on the study. Of these, 17 women were not included in the analysis: Two patients had unreadable slides because of poor processing or insufficient tissue, 2 patients had only slides that were not endometrial, the slides for 5 patients were not available for review, and 8 of the hysterectomy specimens were excluded because they showed evidence of interval intervention, either progestin effect or ablation. In total, 289 patients were included in the current analysis. The study panel review of the AEH biopsy specimens was interpreted as follows: 74 of 289 specimens (25.6%) were diagnosed as less than AEH, 115 of 289 specimens (39.8%) were diagnosed as AEH, and 84 of 289 specimens (29.1%) were diagnosed as endometrial carcinoma. In 5.5% (16 of 289 specimens), there was no consensus on the biopsy diagnosis. The rate of concurrent endometrial carcinoma for analyzed specimens was 42.6% (123 of 289 specimens). Of these, 30.9% (38 of 123 specimens) were myoinvasive, and 10.6% (13 of 123 specimens) involved the outer 50% of the myometrium. Among the women who had hysterectomy specimens with carcinoma, 14 of 74 women (18.9%) had a study panel biopsy consensus diagnosis of less than AEH, 45 of 115 women (39.1%) had a study panel biopsy consensus diagnosis of AEH, and 54 of 84 women (64.3%) had a study panel diagnosis of carcinoma. Among women who had no consensus in their biopsy diagnosis, 10 of 16 women (62.5%) had carcinoma in their hysterectomy specimens.
The prevalence of endometrial carcinoma in patients who had a community hospital biopsy diagnosis of AEH was high (42.6%). When considering management strategies for women who have a biopsy diagnosis of AEH, clinicians and patients should take into account the considerable rate of concurrent carcinoma. Cancer 2006. © 2006 American Cancer Society.